Novartis announces outcomes from Phase III IRIDIUM study for asthma
Category: #health  By Pankaj Singh  Date: 2020-09-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

Novartis announces outcomes from Phase III IRIDIUM study for asthma

Novartis International AG, one of the leading multinational healthcare firms, has reportedly announced outcomes from the crucial Phase III IRIDIUM study of ‘Enerzair Breezhaler’ at ERS( European Respiration Society) International Congress 2020 virtual meet.

Reliable sources cite that high once-daily doses of Enerzair Breezhaler dramatically decrease all moderate-or severe-asthma exacerbation incidence in patients whose asthma is uncontrolled on medium to high dose LABA (Long-acting beta2-agonist)/ ICS (inhaled corticosteroids). 

The analysis also found that the safety profile of Enerzair Breezhaler was compatible with the previous Phase III / IIIb PLATINUM clinical development program.

The study found that a large dose of Enerzair Breezhaler (150/50/160 μg) substantially decreased the annualized risk of mild to serious asthma exacerbations by 21 percent (p=0.026) and extreme exacerbations by 31 percent (p=0.003) in asthma patients not sufficiently managed by current inhaled treatment relative to a standard dose (150/50/80 μg) across 52 weeks.

High-dose Enerzair Breezhaler also decreased the annualized risk of all exacerbations by 14 percent (p=0.132) relative to the medium-dose, although this result was not statistically important. Both doses studied displayed a desirable protection and tolerability profile.

Kenneth Chapman, Professor of Medicine at the University of Toronto, claimed in his comment that this post-hoc study supports the efficacy of high-dose IND / GLY / MF as an important step-up treatment choice to help alleviate asthma exacerbations in patients with uncontrolled asthma. 

For the record, Asthma affects around 358 million people across the globe and could cause a significant health, personal, and financial burden when not effectively controlled. On 7 July 2020, Novartis declared the EC (European Commission) approval of Enerzair Breezhaler for the treatment of asthma in adult patients that are not properly managed with a treatment combination of LABA and a strong dose of ICS. 

Source credit - https://www.novartis.com/news/media-releases/novartis-post-hoc-analysis-shows-high-dose-enerzair-breezhaler-reduces-asthma-exacerbations-versus-medium-dose-complementing-key-pivotal-iridium-study-findings



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

RADLogics obtains FDA's approval for AI-based chest X-Ray App
RADLogics obtains FDA's approval for AI-based chest X-Ray App
By Pankaj Singh

RADLogics Inc., a healthcare software company developing AI-powered solutions has reportedly received 510(k) clearance from the US FDA (Food and Drug Administration) for its latest AI-Powered chest X-ray pneumothorax a...

CDE of China NMPA clears I-Mab’s application for lemzoparlimab
CDE of China NMPA clears I-Mab’s application for lemzoparlimab
By Pankaj Singh

Clinical stage biopharmaceutical major, I-Mab, has reportedly announced that it has received the clearance of the Center for Drug Evaluation of the China National Medical Products Administration for its IND application...

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...